Brian M Wolpin

List of Publications by Year in Descending Order

80 papers	**4,688** citations
32 h-index	**68** g-index
87 ext. papers	**6,340** ext. citations
15.1 avg, IF	**4.97** L-index

#	Paper	IF	Citations
80	A phase 1b study evaluating IL-1β and PD-1 targeting with chemotherapy in metastatic pancreatic cancer (PanCAN-SR1).. *Journal of Clinical Oncology*, **2022**, 40, 557-557	2.2	1
79	G-CSF-induced carotid inflammation.. *Lancet Oncology, The*, **2022**, 23, e235	21.7	1
78	Physical activity in older adults with metastatic gastrointestinal cancer: a pilot and feasibility study. *BMJ Open Sport and Exercise Medicine*, **2022**, 8, e001353	3.4	
77	Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. *Cell*, **2021**, 184, 6119-6137.e26	56.2	13
76	Low glycaemic diets alter lipid metabolism to influence tumour growth. *Nature*, **2021**, 599, 302-307	50.4	24
75	Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. *Cancer Discovery*, **2021**, 11, 2014-2031	24.4	16
74	Identification and management of pathogenic mutations in BRCA1, BRCA2, and PALB2 in a tumor-only genomic testing program.. *Journal of Clinical Oncology*, **2021**, 39, 10528-10528	2.2	1
73	Acquired Resistance to KRAS Inhibition in Cancer. *New England Journal of Medicine*, **2021**, 384, 2382-2393	59.2	91
72	Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. *Clinical Cancer Research*, **2021**, 27, 4574-4586	12.9	11
71	Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. *American Journal of Clinical Nutrition*, **2021**, 114, 1408-1417	7	2
70	Population-Scale CT-based Body Composition Analysis of a Large Outpatient Population Using Deep Learning to Derive Age-, Sex-, and Race-specific Reference Curves. *Radiology*, **2021**, 298, 319-329	20.5	22
69	Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. *Gastroenterology*, **2021**, 160, 1373-1383.e6	13.3	23
68	A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. *Genome Medicine*, **2021**, 13, 15	14.4	6
67	Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. *Cancer Research*, **2021**, 81, 3134-3143	10.1	2
66	Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer. *Journal of Clinical Oncology*, **2021**, 39, 3199-3206	2.2	2
65	Retrospective Case Series Analysis of Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. *JCO Precision Oncology*, **2021**, 5,	3.6	3
64	A 584 bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. *American Journal of Human Genetics*, **2021**, 108, 1852-1865	11	1

63	Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 999-1008	4	7
62	The Mediterranean diet, plasma metabolome, and cardiovascular disease risk. *European Heart Journal*, **2020**, 41, 2645-2656	9.5	54
61	Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 1784-1791	4	4
60	Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. *Cancer Cell*, **2020**, 38, 198-211.e8	24.3	38
59	Discovery of a selective inhibitor of doublecortin like kinase 1. *Nature Chemical Biology*, **2020**, 16, 635-643.	31.7	33
58	Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. *Cancer Research*, **2020**, 80, 4004-4013	10.1	1
57	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. *Nature Communications*, **2020**, 11, 3353	17.4	32
56	BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. *Nature Medicine*, **2020**, 26, 878-885	50.5	126
55	Atypical KRAS Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. *Cancer Discovery*, **2020**, 10, 104-123	24.4	70
54	A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. *Journal of the National Cancer Institute*, **2020**, 112, 1003-1012	9.7	25
53	A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer. *Investigational New Drugs*, **2020**, 38, 1533-1539	4.3	5
52	Imaging-Based Subtypes of Pancreatic Ductal Adenocarcinoma Exhibit Differential Growth and Metabolic Patterns in the Pre-Diagnostic Period: Implications for Early Detection. *Frontiers in Oncology*, **2020**, 10, 596931	5.3	4
51	Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 2735-2739	4	2
50	Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action. *Nature Communications*, **2020**, 11, 4296	17.4	37
49	Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. *Cell Reports*, **2020**, 33, 108493	10.6	7
48	Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. *Investigational New Drugs*, **2020**, 38, 800-811	4.3	52
47	Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. *Cell*, **2020**, 181, 832-847.e18	56.2	34
46	Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). *Journal of the National Cancer Institute*, **2019**, 111, 170-179	9.7	11

45	Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. *Journal of the National Cancer Institute*, **2019**, 111, 557-567	9.7	16
44	Testing for Verification Bias in Reported Malignancy Risks for Side-Branch Intraductal Papillary Mucinous Neoplasms: A Simulation Modeling Approach. *American Journal of Roentgenology*, **2019**, 212, 596-601	5.4	3
43	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. *Nature Communications*, **2018**, 9, 556	17.4	103
42	Characterising -regulatory variation in the transcriptome of histologically normal and tumour-derived pancreatic tissues. *Gut*, **2018**, 67, 521-533	19.2	16
41	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. *Cancer Discovery*, **2018**, 8, 1096-1111	24.4	156
40	When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma. *Journal of Clinical Oncology*, **2017**, 35, 485-489	2.2	8
39	Leucocyte telomere length, genetic variants at the gene region and risk of pancreatic cancer. *Gut*, **2017**, 66, 1116-1122	19.2	28
38	Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148. *Nature Communications*, **2017**, 8, 15034	17.4	26
37	Covariate selection for association screening in multiphenotype genetic studies. *Nature Genetics*, **2017**, 49, 1789-1795	36.3	19
36	Critical role for arginase 2 in obesity-associated pancreatic cancer. *Nature Communications*, **2017**, 8, 242	17.4	47
35	Quantifying the Genetic Correlation between Multiple Cancer Types. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 1427-1435	4	25
34	Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. *Nature*, **2017**, 547, 453-457	50.4	620
33	Reply to A. Braillon. *Journal of Clinical Oncology*, **2017**, 35, 1136-1137	2.2	
32	Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. *Cancer Research*, **2016**, 76, 7160-7167	10.1	32
31	Circulating Exosomes in Pancreatic Cancer: Will They Succeed on the Long, Littered Road to Early Detection Marker?. *Clinical Chemistry*, **2016**, 62, 307-9	5.5	15
30	Winner's Curse Correction and Variable Thresholding Improve Performance of Polygenic Risk Modeling Based on Genome-Wide Association Study Summary-Level Data. *PLoS Genetics*, **2016**, 12, e1006493	6	67
29	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. *Oncotarget*, **2016**, 7, 66328-66343	3.3	66
28	Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 1185-91	4	22

27	Functional characterization of a chr13q22.1 pancreatic cancer risk locus reveals long-range interaction and allele-specific effects on DIS3 expression. *Human Molecular Genetics*, **2016**, 25, 4726-4738	5.6	17
26	Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma. *Hematology/Oncology Clinics of North America*, **2015**, 29, 761-76	3.1	8
25	Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. *Nature Genetics*, **2015**, 47, 911-6	36.3	171
24	Reply to Y. Mao et al. *Journal of Clinical Oncology*, **2015**, 33, 2121-2	2.2	
23	TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. *International Journal of Cancer*, **2015**, 137, 2175-83	7.5	46
22	Characterization of large structural genetic mosaicism in human autosomes. *American Journal of Human Genetics*, **2015**, 96, 487-97	11	77
21	Identification of the Metabolomic Fingerprint Associated with Flavonoid Consumption Level. *FASEB Journal*, **2015**, 29, 745.7	0.9	
20	Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. *Practical Radiation Oncology*, **2014**, 4, e117-e123	2.8	4
19	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. *Nature Genetics*, **2014**, 46, 994-1000	36.3	226
18	Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. *Oncologist*, **2014**, 19, 637-8	5.7	220
17	Variants associated with susceptibility to pancreatic cancer and melanoma do not reciprocally affect risk. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 1121-4	4	14
16	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. *Human Molecular Genetics*, **2014**, 23, 6616-33	5.6	77
15	Hyperglycemia, insulin resistance, impaired pancreatic ß-cell function, and risk of pancreatic cancer. *Journal of the National Cancer Institute*, **2013**, 105, 1027-35	9.7	108
14	Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. *Oncologist*, **2013**, 18, 377-8	5.7	37
13	Plasma 25-hydroxyvitamin D and risk of pancreatic cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 82-91	4	81
12	A phase I study of temsirolimus in combination with gemcitabine in previously untreated metastatic pancreatic cancer.. *Journal of Clinical Oncology*, **2012**, 30, 296-296	2.2	2
11	Feasibility of computer-based self-administered cancer-specific geriatric assessment (SA-CSGA) in older pts with gastrointestinal malignancy (GIM).. *Journal of Clinical Oncology*, **2012**, 30, e19586-e19586	2.2	
10	Variant ABO blood group alleles, secretor status, and risk of pancreatic cancer: results from the pancreatic cancer cohort consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 3140-9	4	67

9	Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. *Cancer Research*, **2010**, 70, 1015-23	10.1	168
8	ABO blood group and the risk of pancreatic cancer. *Journal of the National Cancer Institute*, **2009**, 101, 424-31	9.7	266
7	Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. *Journal of Clinical Oncology*, **2009**, 27, 193-8	2.2	240
6	Clinical problem-solving. The writing on the wall. *New England Journal of Medicine*, **2009**, 361, 1387-92	59.2	4
5	Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. *Journal of Clinical Oncology*, **2009**, 27, 176-85	2.2	183
4	Systemic treatment of colorectal cancer. *Gastroenterology*, **2008**, 134, 1296-310	13.3	364
3	Adjuvant treatment of colorectal cancer. *Ca-A Cancer Journal for Clinicians*, **2007**, 57, 168-85	220.7	193
2	Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. *Cancer Research*, **2007**, 67, 7923-8	10.1	58
1	Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. *Clinical Colorectal Cancer*, **2006**, 6, 208-13	3.8	15